Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms.

Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Abstract Text:

Hongbo Yu,Geraldine S Pinkus,Jason L Hornick,

Podoplanin has been shown to be expressed in primary germ cell tumors (GCTs), with conflicting results regarding its specificity. However, podoplanin expression in metastatic GCTs and other metastatic tumors has not been extensively examined. The goal of this study was to evaluate the distribution and specificity of podoplanin using monoclonal antibody D2-40 in primary testicular and metastatic GCTs in comparison with other metastatic neoplasms. In total, 122 tumors were studied: 43 primary GCTs, 33 metastatic GCTs, 11 metastatic melanomas, 25 metastatic carcinomas, and 10 lymphomas. All foci of seminoma showed strong, diffuse membranous staining in more than 90% of cells in primary and metastatic GCTs. In contrast, other GCT components showed only focal cytoplasmic and/or partial membranous staining in a subset of cases. Among non-GCTs, only 1 metastatic melanoma, 1 lymphoma, and 3 metastatic carcinomas showed focal, weak cytoplasmic staining. Diffuse membranous immunoreactivity for podoplanin as detected by monoclonal antibody D2-40 is highly sensitive and specific for primary and metastatic seminoma. Immunodetection of podoplanin may be useful to support seminoma in the differential diagnosis of poorly differentiated epithelioid malignant neoplasms.

Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Publishing Authors By Initials

H Yu,GS Pinkus,JL Hornick,

For similar biological factors: biological markers: tumor markers, biological research abstracts see: biological factors: biological markers: tumor markers, biological research

PUBMED ID PMID:

MEDLINE DATE:

Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of clinical pathology

VOLUME: 128

Page Numbers: 767-75

Journal Abbreviation: Am. J. Clin. Pathol.

ISSN: 0002-9173

DAY: 29

MONTH: Nov

YEAR: 2007

Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370470

Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Keywords Mesh Terms:

KEYWORDS: Tumor Markers, Biological

MESH TERMS: metabolism

Chemical & Substance for Abstract: Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Information

Substance Name: monoclonal antibody D2-40

Registry Number: 0

Grant and Affiliation Information for Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms.

AFFILIATION: Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Clin Pathol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Diffuse membranous immunoreactivity for podoplanin D2-40 distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms Related Publications

• CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis.
• Chronic alcoholism and the conditioned reflex treatment.
• Clinical studies with the Cendehill strain of attenuated rubella vaccine.
• Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms.
• Effects of acetylated endotoxin in modifying human defense mechanisms.
• Evaluation of antibiotics in a typhoid model.
• Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
• Inflammatory myofibroblastic tumours: where are we now?
• Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors.
• Progenitor cells and vascular disease.